Abstract
The acute and early stages of HIV infection (AEH) are characterized by substantial viral replication, immune activation, and alterations in brain metabolism. However, little is known about the prevalence and predictors of neurocognitive deficits and neuropsychiatric disturbances during this period. The present study examined the impact of demographic, HIV disease, and substance use factors on HIV-associated neurocognitive impairment and self-reported neuropsychiatric distress among 46 antiretroviral-naive adults with median duration of infection of 75 days relative to a sample of 21 HIV seronegative (HIV−) adults with comparable demographics and risk factors. Participants were administered a brief neurocognitive battery that was adjusted for demographics and assessed executive functions, memory, psychomotor speed, and verbal fluency, as well as the Profile of Mood States, a self-report measure of neuropsychiatric distress. Odds ratios revealed that AEH participants were nearly four times more likely than their seronegative counterparts to experience neurocognitive impairment, particularly in the areas of learning and information processing speed. Similarly, AEH was associated with a nearly fivefold increase in the odds of neuropsychiatric distress, most notably in anxiety and depression. Within the AEH sample, HIV-associated neurocognitive impairment was associated with problematic methamphetamine use and higher plasma HIV RNA levels, whereas neuropsychiatric distress was solely associated with high-risk alcohol use. Extending prior neuroimaging findings, the results from this study indicate that HIV-associated neurocognitive impairment and neuropsychiatric distress are highly prevalent during AEH and are associated with high-risk substance use.
Similar content being viewed by others
References
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
Ances BM, Sisti D, Vaida F, Liang CL, Leontiey O, Perthen JE; the HIV Neurobehavioral Research Program (HNRP) Group (2009) Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 73:702–708. doi:10.1212/WNL.0b013e3181b59a97
Atkinson JH, Grant I (1994) Natural history of neuropsychiatric manifestations of HIV disease. Psychiatr Clin N Am 17:17–33
Atkinson JH, Higgins JE, Vigil O, Dubrow R, Remien RH, Steward WT, Grant I (2009) Psychiatric context of acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: IV. AIDS Behav 13:1061–1067. doi:10.1007/s10461-009-9585-3
Barclay TR, Hinkin CH, Castellon SA, Mason KI, Reinhard MJ, Durvasula RS (2007) Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol 26:40–49. doi:10.1037/0278-6133.26.1.40
Battery AIT (1944) Manual of directions and scoring. War Department, Adjutant General’s Office, Washington, DC
Benedict RH, Schretlen D, Groninger L, Brandt J (1998) Hopkins Verbal Learning Test—Revised: normative data and analysis of inter-form and test–retest reliability. Clin Neuropsychol 12:43–55. doi:10.1076/clin.12.1.43.1726
Benton AL, Hamsher K, Sivan AB (1994) Controlled Oral Word Association Test. In: Multilingual aphasia examination, 3rd edn. Iowa City, AJA Associates
Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Douek DC (2004) CD4+ cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200:749–759. doi:10.1084/jem.20040874
Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C; Quebec Primary HIV Infection Study Group (2007) High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 195:951–959
Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte T D, Grant I; The HNRC Group (2004a) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26:307–319
Carey CL, Woods SP, Rippeth JD, Gonzalez R, Moore DJ, Marcotte TD; The HNRC Group (2004b) Initial validation of a screening battery for the detection of HIV-associated neurocognitive impairment. Clin Neuropsychol 18:234–248
Carey CL, Woods SP, Rippeth JD, Heaton RK, Grant I, The HNRC Group (2006) Prospective memory in HIV-1 infection. J Clin Exp Neuropsychol 28:536–548
Cattie JE, Doyle K, Weber E, Grant I, Woods SP, The HNRP Group (2012). Planning deficits in HIV-associated neurocognitive disorders: Component processes, cognitive correlates, and implications for everyday functioning. J Clin Exp Neuropsychol 34:906–918
Chana G, Everall IP, Crews L, Langford D, Adame A, Grant I; The HNRC Group (2006) Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 67:1486–1489
Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Grant I; the CHARTER Group (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25:1747–1751
Gavin DR, Ross HE, Skinner HA (1989) Diagnostic Validity of the Drug Abuse Screening Test in the assessment of DSM-III drug disorders. Br J Addict 84:301–307. doi:10.1111/j.1360-0443.1989.tb03463.x
Gavrilin MA, Mathes LE, Podell M (2002) Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol 8:240–249. doi:10.1080/13550280290049660
Gorman AA, Foley JM, Ettenhofer ML, Hinkin CH, van Gorp WG (2009) Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev 19:186–203. doi:10.1007/s11065-009-9095-0
Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, Grant I; The HNRC Group (2004a) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10:317–331. doi:10.1017/S1355617704102130
Heaton RK, Miller SW, Taylor MJ, Grant I (2004b) Revised comprehensive norms for an expanded Halstead-Reitan Battery: demographically adjusted neuropsychological norms for African American and Caucasian adults. Psychological Assessment Resources, Inc., Odessa, FL
Heaton RK, Clifford DB, Franklin DR Jr., Woods SP, Ake C, Vaida F; The CHARTER Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096
Heaton RK, Franklin DR Jr., Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S; The HNRC Group (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3–16
Kamat R, Woods SP, Marcotte TD, Ellis RJ, Grant I (2012) Implications of apathy for everyday functioning outcomes in persons living with HIV infection. Arch Clin Neuropsychol 27(5):520–531
Kennedy CA, Skurnick J, Wan J, Quattrone G, Sheffet A, Quinones M, Louria D (1993) Psychological distress, drug and alcohol use as correlates of condom use in HIV-serodiscordant heterosexual couples. AIDS 7:1493–1499. doi:10.1097/00002030-199311999-00014
Kerndt PR, Dubrow R, Aynalem G, Mayer KH, Beckwith C, Remein RH, Morin SF (2009) Strategies used in the detection of acute/early HIV infections. The NIMH Multisite Acute HIV Infection Study: I. AIDS Behav 13:1037–1045. doi:10.1007/s10461-009-9580-8
Kløve H (1963) Grooved pegboard. Lafayette Instruments, Lafayette, IN
Lentz MR, Kim WK, Lee V, Bazner S, Halpern EF, Venna N, Gonzalez RG (2009) Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology 72:1465–1472. doi:10.1212/WNL.0b013e3181a2e90a
Lentz MR, Kim WK, Kim H, Soulas C, Lee V, Venna N, Gonzalez RG (2011) Alterations in brain metabolism during the first year of HIV infection. J Neurovirol 17:220–229. doi:10.1007/s13365-011-0030-9
Lyles RH, Munoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, Mellors JW for the Multicenter AIDS Cohort Study (2000) Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J Infect Dis 181:872–880. doi:10.1086/315339
Marcotte TD, Deutsch R, McCutchan JA, Moore DJ, Letendre S, Ellis RJ, Grant I, for the HIV Neurobehavioral Research Center (HNRC) Group (2003) Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol 60:1406–1412
McNair DM, Loor M, Droppleman LF (1981) Profile of mood states. Educational and Industrial Testing Service, San Diego, CA
Moore DJ, Letendre SL, Morris S, Umlauf A, Deutsch R, Smith DM, Grant I for the CHARTER Group (2011) Neurocognitive functioning in acute or early HIV infection. J Neurovirol 17:50–57. doi:10.1007/s13365-010-0009-y
Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, Heaton RK, Grant I; the HNRP Group and the TMARC Group (2012) Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care: Psychological and Socio-medical Aspects of AIDS/HIV 24:1504–1513. doi:10.1080/09540121.2012.672718
Norman MA, Moore DJ, Taylor MJ, Franklin D, Cysique L, Ake C, Heaton RK; the HNRC Group (2011) Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64—Card Version. J Clin Exp Neuropsychol 33:793–804. doi:10.1080/13803395.2011.559157
Nyenhuis DK, Yamamoto C, Luchetta T, Terrien A, Parmentier A (1999) Adult and geriatric normative data and validation of the profile of mood states. J Clin Psychol 55:79–86. doi:10.1002/(SICI)1097-4679(199901)55:1<79::AID-JCLP8>3.0.CO;2-7
Pao D, Fisher M, Hue S, Dean G, Murphy G, Cane PA, Pillay D (2005). Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 19:85–90. doi:10.1097/00002030-200501030-00010
Perry S, Jacobsberg L, Card CA, Ashman T, Frances A, Fishman B (1993) Severity of psychiatric symptoms after HIV testing. Am J Psychiatry 150:775–779
Pilcher CD, Tien HC, Eron JJ, Vernazza PL, Leu SY, Stewart PW, Cohen MS (2004). Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 189:1785–1792. doi:10.1086/386333
Plankey MW, Ostrow DG, Stall R, Cox C, Li X, Peck JA, Jacobson L (2007) The relationship between methamphetamine and popper use and risk of HIV seroconversion in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 45:85–92. doi:10.1097/QAI.0b013e3180417c99
Raj A, Reed E, Santana MC, Walley AY, Welles SL, Horsburgh CR, Silverman JG (2009) The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. Drug Alcohol Depend 101:101–106
Reinert DF, Allen JP (2007) Alcohol Use Disorders Identification Test: an update of research findings. Alcohol Clin Exp Res 31:185–199. doi:10.1111/j.1530-0277.2006.00295.x
Rippeth, JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R, Grant I.; and the HNRC Group (2004) Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10:1–14. doi:10.1017/S1355617704101021
Rosenbloom MJ, Sullivan EV, Sassoon SA, O-Reilly A, Fama R, Kemper CA, Pfefferbaum A (2007) Alcoholism, HIV infection, and their comorbidity: factors affecting self-rated health-related quality of life. J Stud Alcohol Drugs 68:115–125
Rourke SB, Halman MH, Bassel C (1999) Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning. J Clin Exp Neuropsychol 21:737–756
Saunders JB, Aasland OG, Barbor TF, De La Fuente JR, Grant M (1993) Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption—II. Addiction 88:791–804. doi:10.1111/j.1360-0443.1993.tb02093.x
Schacker T, Collier AC, Hughes J, Shea T, Corey L (1996) Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 125:257–264
Schacker T, Hughes JP, Shea T, Coombs RW, Corey L (1998) Biological and virologic characteristics of primary HIV infection. Ann Intern Med 128:613–620
Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17:275–297
Sevigny JJ, Albert SM, McDermott MP, Schifitto G, McArthur JC, Sacktor N, … Epstein LG (2007) An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 64:97–102
Skinner HA (1982) The Drug Abuse Screening Test. Addict Behav 7:363–371
Steele CM, Southwick L, Pagano R (1986) Drinking your troubles away: the role of activity in mediating alcohol’s reduction of psychological stress. J Abnorm Psychol 95:173–180
Tambussi G, Gori A, Capiluppi B, Balotta C, Papagno L, Morandini B, Lazzarin A (2000) Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis 30:962–965. doi:10.1086/313810
Tucker JS, Burnam MA, Sherbourne CD, Kung FK, Gifford AL (2003) Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 114:573–580. doi:10.1016/S0002-9343(03)00093-7
Wang X, Foryt P, Ochs R, Chung JH, Wu Y, Parrish T, Ragin AB (2011) Abnormalities in resting-state functional connectivity in early human immunodeficiency virus infection. Brain Connectivity 1:207–217. doi:10.1089/brain.2011.0016
Weber E, Blackstone K, Iudicello JE, Morgan EE, Grant I, Moore DJ; The TMARC Group (2012) Neurocognitive deficits are associated with unemployment in chronic methamphetamine users. Drug Alcohol Depend 125:146–153
Weinhart LS, Carey MP (2000) Does alcohol lead to sexual risk behavior? Findings from event-level research. Ann Rev Sex Res 11:125–157
Wilkinson GS (1993) Wide Range Achievement Test Administration Manual, 3rd edn. Wide Range, Inc., Wilmington, DE
Woods SP, Rippeth JD, Conover E, Gongvatana A, Gonzalez R, Carey CL; The HNRC Group (2005b) Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence. Neuropsychology 19:35–43
Woods SP, Scott JC, Sires DA, Grant I, Heaton RK, Tröster AI; the HNRC Group (2005a) Action (verb) fluency: test–retest reliability, normative standards, and construct validity. J Int Neuropsychol Soc 11:408–415. doi:10.1017/S1355617705050460
World Health Organization (1998) Composite International Diagnostic Interview (CIDI, version 2.1). World Health Organization, Geneva
Yudko E, Lozhkina O, Fouts A (2007) A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abus Treat 32:189–198. doi:10.1016/j.jsat.2006.08.002
Zetola NM, Pilcher CD (2007) Diagnosis and management of acute HIV infection. Infect Dis Clin North Am 21:19–48. doi:10.1016/j.idc.2007.01.008
Acknowledgments
The Translational Methamphetamine AIDS Research Center (TMARC) group is affiliated with the University of California, San Diego (UCSD), and the Sanford-Burnham Medical Research Institute. The TMARC comprised Director: Igor Grant, MD; Co-Directors: Ronald J. Ellis, MD, PhD, Cristian Achim, MD, PhD, and Scott Letendre, MD; Center Manager: Steven Paul Woods, PsyD; Aaron Carr (Assistant Center Manager); Clinical Assessment and Laboratory Core: Scott Letendre, MD (P.I.), Ronald J. Ellis, MD, PhD, Rachel Schrier, PhD; Neuropsychiatric Core: Robert K. Heaton, PhD (P.I.), J. Hampton Atkinson, MD, Mariana Cherner, PhD, Thomas Marcotte, PhD; Neuroimaging Core: Gregory Brown, PhD (P.I.), Terry Jernigan, PhD, Anders Dale, PhD, Thomas Liu, PhD, Miriam Scadeng, PhD, Christine Fennema-Notestine, PhD, Sarah L. Archibald, MA; Neurosciences and Animal Models Core: Cristian Achim, MD, PhD, Eliezer Masliah, MD, Stuart Lipton, MD, PhD; Participant Unit: J. Hampton Atkinson, MD, Rodney von Jaeger, MPH (Unit Manager); Data Management and Information Systems Unit: Anthony C. Gamst, PhD, Clint Cushman (Unit Manager); Statistics Unit: Ian Abramson, PhD (P.I.), Florin Vaida, PhD, Reena Deutsch, PhD, Anya Umlauf, MS; Project 1: Arpi Minassian, PhD (P.I.), William Perry, PhD, Mark Geyer, PhD, Brook Henry, PhD; Project 2: Amanda B. Grethe, PhD (P.I.), Martin Paulus, MD, Ronald J. Ellis, MD, PhD; Project 3: Sheldon Morris, MD, MPH (P.I.), David M. Smith, MD, MAS, Igor Grant, MD; Project 4: Svetlana Semenova, PhD (P.I.), Athina Markou, PhD; Project 5: Marcus Kaul, PhD (P.I.). This research was supported by National Institutes of Health grants P01-DA12065, P50-DA026306, P30-MH62512, T32-DA31098, DA-034510, DA-032120, DA-034362, AI-090970, AI-100665, AI-080353, MH-097520, DA-034978, MH-83552, MH-62512, AI-74621, AI-36214, TW-008908, AI-69432, AI-096113, and AI-47745. This work was additionally supported by the Department of Veterans Affairs and grants awarded from the International AIDS Vaccine Initiative (IAVI), the National Science Foundation DMS0714991, and the James B. Pendleton Charitable Trust. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, nor the United States Government.
Disclosure
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Weber, E., Morgan, E.E., Iudicello, J.E. et al. Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J. Neurovirol. 19, 65–74 (2013). https://doi.org/10.1007/s13365-012-0141-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13365-012-0141-y